Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DuoNen tandem radionuclide therapy for gastroenteropancreatic neuroendocrine neoplasms
2020-006068-99Phase 3Active
- Sponsor
- Radioisotope Centre POLATOM
- Start
- Jan 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177 dotatate and 90Y-DOTATATE in gastroenteropancreatic neuroendocrine tumor (GEP-NET) (2 arms), sponsored by Radioisotope Centre POLATOM. Primary endpoint: Disease progression. Started Jan 2021; status: active.
02
Drugs
lutetium Lu 177 dotatate90Y-DOTATATE
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on 2020-006068-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006068-99.